SOURCE: Proteonomix, Inc

Proteonomix, Inc

August 04, 2009 10:45 ET

Proteonomix, Inc. (PROT) Files a Registration Statement With the USSEC on Form 10 to Become a Reporting Company -- the Gateway to the Trading of Its Common Stock on the OTC Bulletin Board

MOUNTAINSIDE, NJ--(Marketwire - August 4, 2009) - Proteonomix, Inc. (PINKSHEETS: PROT) announced today that it has filed a registration statement with the Securities and Exchange Commission on Form 10. Its shares can trade on the Over the Counter Bulletin Board when the registration statement is effective and FINRA grants clearance.

Michael Cohen, President, stated, "Our stem cell-derived technologies are cutting edge. We identify biomarkers, cell derivatives and cellular proteins, for the development of stem cell therapies for disease and injury. Our subsidiary, Proteoderm, has designed and produced an anti-aging cosmeceutical and other cosmetics derived from our patent pending Matrix NC-138™.

"By becoming an SEC reporting company, we seek the same recognition in the financial community as we have gained in the biomedical community.

"This filing marks our first with our new auditors, KBL LLP, and we look forward to their review of our quarterly reports and the audit of our annual reports."

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, Inc. has developed a line of anti-aging cosmetics. For more information, please visit or and

"Safe Harbor Statement."

Under the Private Securities Litigation Reform Act of 1995, all statements other than statements of historical fact included in this press release are "forward-looking statements." Such forward-looking statements are subject to a number of risks and uncertainties. Statements which address our financial or business outlook, apply only as of the date the information was issued; and anticipated financial results may not occur.

Contact Information

  • Contact:
    Michael Cohen
    Proteonomix, Inc.
    Phone: (973) 544-6116
    Email Contact